olfactory receptor family 56 subfamily A member 3Genealiases: OR56A2P · OR56A3P · OR56A6
Q-omics provides the consensus-scored OR56A3 profile across patient tissues and cancer cell-line models. OR56A3 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in TGCT. Among the 18 cancer types available for tumor–normal comparison, OR56A3 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, OR56A3 RNA expression shows 6,075 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight TGCT, BRCA, and STAD as cancer lineages where OR56A3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR56A3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR56A3 survival associations across molecular data types. OR56A3 RNA expression shows survival associations in the most cancer types (14), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR56A3 RNA expression–survival associations across cancer types. High OR56A3 expression shows unfavorable associations in TGCT, ACC, BRCA, LIHC, COAD and PAAD. The TGCT Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify TGCT as the clearest survival context for OR56A3 RNA expression.
This table summarizes OR56A3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for OR56A3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR56A3 shows higher tumor expression in BRCA, LUAD, LIHC and LUSC. The BRCA box plot shows higher OR56A3 RNA expression in tumor versus normal tissue (log2 FC = +0.120, t-test p = .004).
This table shows molecular features associated with OR56A3 in patient tissues and cancer cell lines. In patient samples, OR56A3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, OR56A3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
